Drug Approval | October 09, 2022
Dipharma receives regulatory authorization for the new line at Its cGMP pilot plant
The company increases its efficiency and is able to face the growing demand for its services.
The company increases its efficiency and is able to face the growing demand for its services.
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.
Construction is now underway with the facility scheduled to be operational by 2025
Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
This inspection continues a series of successful inspections by Swissmedic in Vionnaz with the first inspection in 2015 followed by 2016, 2017 and 2020.
Transformation to pure-play Innovative Medicines company nears completion
Subscribe To Our Newsletter & Stay Updated
